Shopping the best Chromebooks can be a great way to save some money if you only need the bare essentials in a laptop. The IdeaPad Slim 3 Chromebook has, for the most part, entry-level specs, but ...

Moreover, the first X1 Carbon Gen 13 models skip the entry-level (Core i5, full HD IPS screen) configurations and get right ...

The Lenovo ThinkPad X1 Carbon Gen 13 is an excellent laptop at a high price. It's best suited for ThinkPad fans, and it's the best ever for them.

The Lenovo ThinkPad X1 Carbon Gen 13 Aura Edition has elegance and feels great to use. But Lenovo should have stepped up its ...

Rule the workplace with the Lenovo ThinkPad X1 Carbon Gen 11. Get this powerhouse business laptop for only $1,421 while ...

Lenovo ThinkPad X1 Carbon Gen 11 is a Windows 11 laptop with a 14.00-inch display. It is powered by a Core processor and it comes with 64GB of RAM. The Lenovo ThinkPad X1 Carbon Gen 11 packs 2TB of ...

Possible alternatives to a manned 6th-generation combat jet include a more affordable, “F-35 follow- on” aircraft that could manage robot wingmen, the outgoing Air Force secretary said.

Media reports show that China test-flew two different versions of future sixth-generation stealth fighter jets in late December. America's Air Force is still flying fifth-generation fighter jets ...

Lenovo ThinkPad X1 Yoga Gen 8 is a Windows 11 laptop with a 14.00-inch display. It is powered by a Core processor and it comes with 64GB of RAM. The Lenovo ThinkPad X1 Yoga Gen 8 packs 2TB of SSD ...

Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of ...

Lockheed Martin (NYSE: LMT) builds America's only two fifth-generation "stealth" fighter jets, the F-22 Raptor (production of which has already ceased) and the F-35 Lightning II (production of ...

Novo Nordisk (NVO) plunged to a 52-week low on Friday after the Danish drugmaker released Phase 3 results for its next-gen weight loss therapy, CagriSema, as data gave a pause for its investors ...